Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating imatinib and regorafenib versus imatinib alone for metastatic GIST
ACTRN12614000950662Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Alternating imatinib and regorafenib with Continuous imatinib (2 arms). Primary endpoint: Objective tumour response. Started Jun 2015; status: completed.
02
Drugs
imatinibregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ACTRN12614000950662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000950662.